Adaptimmune Therapeutics Plc ADR (ADAPY)

$0.05 0.00 (-1.82%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 45,989,301
Avg Vol 115,232,406
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 15%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 12 3543 0000
Address:
60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom
US_Bull
US_Bull Mar. 21 at 6:56 PM
$ADAPY Guys before you go all overboard with this reverse merger theory fact remains that USW still states on their website the below. I think a more realistic take is they privatize us and stay private there is nothing that says that them partnering with us fully has to happen by reverse merger. It could be a cash BO. At least that is still my theory. I think they intend to stay private for the forseable future. I think they want to see first how the cell therapy business goes they don't become cash flow profitable over night lol especially with a brand new technology they don't yet master. I think also part of the reason they got the credit is for the second part to play out. Like Piper said the 55 million asset sale was the first act before the second act.
1 · Reply
BK217
BK217 Mar. 21 at 6:35 PM
$ADAPY
0 · Reply
alen1
alen1 Mar. 21 at 6:24 PM
$ADAPY What’s actually left in the company? Cash (mid-2025): ~$26M  Tecelra sale: $55M upfront + up to $30M milestones  Guaranteed cash ≈ $80M total (26M + 55M)Milestones ($30M) Share count reality You mentioned ~265M ADR shares That’s a reasonable ballpark for dilution-adjusted count. Base liquidation math Conservative $80M / 265M shares ≈ $0.30 Mid-case ~$95M / 265M ≈ $0.35–$0.40 Bull case $110M+ / 265M ≈ $0.40–$0.50 Burning cash Restructuring heavily Cutting workforce ~60% Already flagged going concern risk $0.20 – $0.40 is the realistic liquidation band Step 5: If it’s NOT liquidation Typical outcome: Short term: $0.05–$0.20 Long term: depends entirely on new company Typical range: $0.30 – $0.60 per share Most realistic range: 0.20 – $0.50 per share Probability-weighted view: Scenario Probability Value Liquidation Medium-High$0.20–$0.40 Buyout Medium $0.30–$0.60 Reverse merger Medium $0.05–$0.30
0 · Reply
PaidPiper
PaidPiper Mar. 21 at 6:11 PM
$ADAPY without retail involved the climb would be more steady and controlled but not as lucradive of a spike is what I'm thinking. No panic selling and anyone buying is buying with intent to hold through a reverse merger. Easier for us to exit in small tranches but a hyped re-rating to $5 then pullback is probably not gonna happen here
0 · Reply
PaidPiper
PaidPiper Mar. 21 at 5:58 PM
$ADAPY slight change to the theory. They probably won't file an 8K since they are non-reporting. I'm thinking a press release is far more likely and those always show up here first: https://find-and-update.company-information.service.gov.uk/company/09338148/filing-history
2 · Reply
PaidPiper
PaidPiper Mar. 21 at 5:18 PM
$ADAPY if we're assuming USWM CT LLC is the party involved, then a reverse merger would be the best possible outcome for us. Worst would be an asset sale unless they pay us a fortune for the vector platform. But they didn't create the subsidiary and start hiring for a CT ramp up in Philly just to buy the remaining assets, otherwise ADAP wouldn't have cleaned it's shell. They would've liquidated in August.
1 · Reply
alen1
alen1 Mar. 21 at 4:10 PM
$ADAPY 📊 About the ~265M ADR shares This is key: • High share count = caps per-share buyout price • Buyers look at: 👉 total deal value, not share price Example: • $100M deal ÷ 265M shares ≈ $0.38/share • $50M deal ≈ $0.19/share 👉 That’s why most realistic BO range stays: • $0.10 – $0.30 ⸻ 🎯 What actually matters (not wording) Focus on: 1. Cash runway (Q2 2026 pressure) 2. Any official strategic review / deal announcement 3. Who’s bidding (1 buyer vs multiple) ⸻ 🧠 Bottom line • “Stakeholders” = neutral, standard • RS = still possible if no deal soon • Share count = limits upside per share
1 · Reply
alen1
alen1 Mar. 21 at 4:10 PM
$ADAPY AI respond by all info on the company don’t read too much into that wording — it’s not a signal of a reverse split or guaranteed buyout. Stakeholders” wording — does it matter? From Adaptimmune Therapeutics plc PR language: • “Maximize value for stakeholders” = standard legal phrasing • It means: • shareholders • creditors • partners Neutral overall • Positive: they’re signaling value creation / sale process • Negative: includes creditors → could justify a lowball deal if distressed ⚠️ Reverse split (RS) — is it off the table? 👉 Not guaranteed either way. • If buyout happens soon → RS likely not needed • If delays / cash issues → RS still very possible 👉 So: • Your thesis reduces RS risk • But doesn’t eliminate it⸻
0 · Reply
duepillagence
duepillagence Mar. 21 at 3:45 PM
$ADAPY So a subsidiary is merging with a shell? I don't believe that a RS is on the table here. Remember within the Tecelra sale pr readout, they used the term "steak holders" when saying they would maximize value? Does this line of wording have any significance negative or positive, and how might this impact 265 mil adr shares? I honestly don't know...
1 · Reply
Damage111
Damage111 Mar. 21 at 12:32 AM
$ADAPY I sure would like this to end soon with a big paycheck 💰💰💰
1 · Reply
Latest News on ADAPY
No data available.
US_Bull
US_Bull Mar. 21 at 6:56 PM
$ADAPY Guys before you go all overboard with this reverse merger theory fact remains that USW still states on their website the below. I think a more realistic take is they privatize us and stay private there is nothing that says that them partnering with us fully has to happen by reverse merger. It could be a cash BO. At least that is still my theory. I think they intend to stay private for the forseable future. I think they want to see first how the cell therapy business goes they don't become cash flow profitable over night lol especially with a brand new technology they don't yet master. I think also part of the reason they got the credit is for the second part to play out. Like Piper said the 55 million asset sale was the first act before the second act.
1 · Reply
BK217
BK217 Mar. 21 at 6:35 PM
$ADAPY
0 · Reply
alen1
alen1 Mar. 21 at 6:24 PM
$ADAPY What’s actually left in the company? Cash (mid-2025): ~$26M  Tecelra sale: $55M upfront + up to $30M milestones  Guaranteed cash ≈ $80M total (26M + 55M)Milestones ($30M) Share count reality You mentioned ~265M ADR shares That’s a reasonable ballpark for dilution-adjusted count. Base liquidation math Conservative $80M / 265M shares ≈ $0.30 Mid-case ~$95M / 265M ≈ $0.35–$0.40 Bull case $110M+ / 265M ≈ $0.40–$0.50 Burning cash Restructuring heavily Cutting workforce ~60% Already flagged going concern risk $0.20 – $0.40 is the realistic liquidation band Step 5: If it’s NOT liquidation Typical outcome: Short term: $0.05–$0.20 Long term: depends entirely on new company Typical range: $0.30 – $0.60 per share Most realistic range: 0.20 – $0.50 per share Probability-weighted view: Scenario Probability Value Liquidation Medium-High$0.20–$0.40 Buyout Medium $0.30–$0.60 Reverse merger Medium $0.05–$0.30
0 · Reply
PaidPiper
PaidPiper Mar. 21 at 6:11 PM
$ADAPY without retail involved the climb would be more steady and controlled but not as lucradive of a spike is what I'm thinking. No panic selling and anyone buying is buying with intent to hold through a reverse merger. Easier for us to exit in small tranches but a hyped re-rating to $5 then pullback is probably not gonna happen here
0 · Reply
PaidPiper
PaidPiper Mar. 21 at 5:58 PM
$ADAPY slight change to the theory. They probably won't file an 8K since they are non-reporting. I'm thinking a press release is far more likely and those always show up here first: https://find-and-update.company-information.service.gov.uk/company/09338148/filing-history
2 · Reply
PaidPiper
PaidPiper Mar. 21 at 5:18 PM
$ADAPY if we're assuming USWM CT LLC is the party involved, then a reverse merger would be the best possible outcome for us. Worst would be an asset sale unless they pay us a fortune for the vector platform. But they didn't create the subsidiary and start hiring for a CT ramp up in Philly just to buy the remaining assets, otherwise ADAP wouldn't have cleaned it's shell. They would've liquidated in August.
1 · Reply
alen1
alen1 Mar. 21 at 4:10 PM
$ADAPY 📊 About the ~265M ADR shares This is key: • High share count = caps per-share buyout price • Buyers look at: 👉 total deal value, not share price Example: • $100M deal ÷ 265M shares ≈ $0.38/share • $50M deal ≈ $0.19/share 👉 That’s why most realistic BO range stays: • $0.10 – $0.30 ⸻ 🎯 What actually matters (not wording) Focus on: 1. Cash runway (Q2 2026 pressure) 2. Any official strategic review / deal announcement 3. Who’s bidding (1 buyer vs multiple) ⸻ 🧠 Bottom line • “Stakeholders” = neutral, standard • RS = still possible if no deal soon • Share count = limits upside per share
1 · Reply
alen1
alen1 Mar. 21 at 4:10 PM
$ADAPY AI respond by all info on the company don’t read too much into that wording — it’s not a signal of a reverse split or guaranteed buyout. Stakeholders” wording — does it matter? From Adaptimmune Therapeutics plc PR language: • “Maximize value for stakeholders” = standard legal phrasing • It means: • shareholders • creditors • partners Neutral overall • Positive: they’re signaling value creation / sale process • Negative: includes creditors → could justify a lowball deal if distressed ⚠️ Reverse split (RS) — is it off the table? 👉 Not guaranteed either way. • If buyout happens soon → RS likely not needed • If delays / cash issues → RS still very possible 👉 So: • Your thesis reduces RS risk • But doesn’t eliminate it⸻
0 · Reply
duepillagence
duepillagence Mar. 21 at 3:45 PM
$ADAPY So a subsidiary is merging with a shell? I don't believe that a RS is on the table here. Remember within the Tecelra sale pr readout, they used the term "steak holders" when saying they would maximize value? Does this line of wording have any significance negative or positive, and how might this impact 265 mil adr shares? I honestly don't know...
1 · Reply
Damage111
Damage111 Mar. 21 at 12:32 AM
$ADAPY I sure would like this to end soon with a big paycheck 💰💰💰
1 · Reply
BassBb
BassBb Mar. 20 at 11:01 PM
$ADAPY Don't have unnecessary expectations and think that the announcement will be made in June.
1 · Reply
Stockinvestor73
Stockinvestor73 Mar. 20 at 10:54 PM
$ADAPY
0 · Reply
PaidPiper
PaidPiper Mar. 20 at 10:51 PM
$ADAPY I started thinking why are we automatically assuming the generic 90/10 RM split? We aren't the typical strugglic shell biotech. If this is even partially true, it's a game changer for us. I think 60% would be a miracle but 30-40% is more than fair. Right?
1 · Reply
PaidPiper
PaidPiper Mar. 20 at 9:02 PM
$ADAPY 530pm is the 'curtains closed' for all major SEC filings in case you didn't know. I'm not just choosing arbitrary times. If it's submitted 1 second after 530pm it would show up on mondays filings instead. Still checking, still nothing. Also it won't be on adaps site first but the sec.gov site. Their personal site could take minutes to several hours to post the 8k
1 · Reply
Hodl707
Hodl707 Mar. 20 at 8:26 PM
$ADAPY USWM CT LLC reverse merges into Adaptimmune shell. Combined NewCo holds everything: ∙ TECELRA commercial ∙ Lete-cel pipeline ∙ PRAME franchise ∙ CD70 program ∙ 700 patents complete ∙ Full manufacturing ∙ All partnerships
0 · Reply
PaidPiper
PaidPiper Mar. 20 at 8:17 PM
$ADAPY WOULDN'T be on the RNS** ⬇️
0 · Reply
PaidPiper
PaidPiper Mar. 20 at 8:16 PM
$ADAPY reminder: if news came out now it would be on the RNS, that closes at 630pm UK. It would be in the form of an 8k filed with the SEC and the UK RNS would post it forst thing monday morning. I checked and nothing yet
1 · Reply
Pimpdaddiaddi
Pimpdaddiaddi Mar. 20 at 6:39 PM
$ADAPY I dangled a couple shares at .03 to see what happens
2 · Reply
952_
952_ Mar. 20 at 6:38 PM
$ADAPY this is tempting
0 · Reply
Hodl707
Hodl707 Mar. 20 at 6:34 PM
$ADAPY the realty !! This can’t go on much longer money is running out somthing need a to happen !! Fact time is on our side !!
0 · Reply
PaidPiper
PaidPiper Mar. 20 at 5:54 PM
$ADAPY not much selling at 2 cents either. Move the bid up some more! Try 3
0 · Reply
Neema1005
Neema1005 Mar. 20 at 5:42 PM
$ADAPY Why is that graph funky? going horizontally like that?
1 · Reply